Milestone Pharmaceuticals Inc. (MIST) Stock

About Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. is led by CEO Joseph G. Oliveto, publicly traded since 2019.

Milestone Pharmaceuticals Inc. (MIST) stock trades at $0.65 with a market capitalization of $80.70M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.17, reflecting a net loss over the last twelve months, price-to-book of 6.16, price-to-sales of 43.02. Over the past 52 weeks the stock has ranged between $0.64 and $3.06, and currently trades 78.8% below its 52-week high.

On profitability, Milestone Pharmaceuticals Inc. generates a return on equity (ROE) of -288.36% (negative, reflecting a net loss), return on capital employed of -49.27%, an operating margin of -3100.00%, a net profit margin of -38.32%.

Milestone Pharmaceuticals Inc. by the numbers, 2017–2025

Between 2017 and 2025 Milestone Pharmaceuticals Inc. reported revenue of $0 rising to $2.0M. Compounded, revenue has grown —% a year over five years, -26.3% over three, —% over the last twelve months. Net profit fell to $-63.0M.

The most recent net margin is -38.32%. On a trailing twelve-month basis to Jun '26, revenue is $3.0M and net profit $-84.0M.

Borrowings stand at $58.0M, cash from operations was $-49.0M in the latest year, positive in 0 of the last 9.

Return on equity has averaged -190.4% over five years, and was -150.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Milestone Pharmaceuticals Inc. (MIST) — frequently asked questions